Shenzhen Component Index fell more than 1%; Xingchen Technology dropped over 11%, leading decliners among index constituents.

Changchun High & New Technology Industry (Group) Co., Ltd’s unit Changchun Jinsai Pharmaceutical Co., Ltd received a Drug Clinical Trial Approval Notice from the National Medical Products Administration approving a domestically manufactured drug‑registration clinical trial application for injectable GenSci136. GenSci136 is Jinsai’s self‑developed BAFF/APRIL dual‑target antagonist, classified in China as a Class 1 therapeutic biological product and intended for treatment of Sjögren’s syndrome.

Hong Kong-listed Xiaomi Corp (01810.HK) fell over 5% with turnover near CNY 2.9 bln.